Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients? Commentary

Nature Clinical Practice Oncology

Volumn 5, Issue 2, 2008, Pages 70-71

  van Rhee, Frits ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG RESPONSE; HIGH RISK POPULATION; HUMAN; INFECTION; INTERMETHOD COMPARISON; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; SHORT SURVEY; SURVIVAL RATE; SURVIVAL TIME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; HUMANS; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 38849164201     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1005     Document Type: Short Survey

References (4)

1. Pui CH and Evans WE (2006) Drug therapy: Treatment of acute lymphoblastic leukemia. N Engl J Med 354: 166-178
2. Attal M et al. (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349: 2495-2502
3. Abdelkefi A et al. (2007) Single autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood [doi:10.1182/blood-2007-07-101212]
4. Shaughnessy JD Jr et al. (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109: 2276-2284